Company Overview

Memory Pharmaceuticals Corp., a biopharmaceutical company, develops drugs for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company’s products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer’s disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzh...

Memory Pharmaceuticals Corp., a biopharmaceutical company, develops drugs for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company’s products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer’s disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzheimer’s disease and CIAS. Its products also comprise PDE4 inhibitors, including MEM 1414, a phase I clinical trial program, as well as MEM 1917 for CNS disorders and depression; PDE10 Inhibitor program; and 5-HT6 Antagonists for the treatment of Alzheimer’s disease, schizophrenia, attention deficit disorder, and obesity. The company has collaborations with F. Hoffman-La Roche, Ltd. for the development of nicotinic alpha-7 agonists; and Amgen, Inc. for the development of PDE10 inhibitors. In addition, it has a development agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was incorporated in 1997 and is based in Montvale, New Jersey. As of December 31, 2008, Memory Pharmaceuticals Corp. operates as a subsidiary of Hoffmann-La Roche Inc.

Key Executives for Memory Pharmaceuticals Corp.

Similar Private Companies By Industry

Recent Private Companies Transactions